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Overview
========

Occupational exposures are important, frequently overlooked, and modifiable contributors to the burden of respiratory disease. Quantifying the occupational contribution to this disease burden is critical to preventing disease and improving lung health. To date, the question of the occupational burden in respiratory disease at the population level has been addressed primarily in relation to asthma and chronic obstructive pulmonary disease (COPD). This document reviews and synthesizes existing data to quantify the occupational contribution to the burden of nonmalignant respiratory diseases across a range of conditions frequently unrecognized as potentially work related.

Key Conclusions
---------------

•A substantial evidence base indicates that the contribution of inhalational workplace hazards to the burden of nonmalignant lung diseases is substantial.•Conditions for which the estimated occupational burden is 10% or more include asthma, COPD, chronic bronchitis, idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis (HP), other noninfectious granulomatous lung diseases (including sarcoidosis), pulmonary alveolar proteinosis (PAP), and community-acquired pneumonia (CAP).•These findings highlight the need for greater awareness that work exposures contribute substantially across a range of respiratory diseases.•Strategies are needed to improve the recognition and prevention of the substantial occupational burden of nonmalignant respiratory diseases.

Introduction
============

Inhalation of vapors, gas, dust, or fumes (VGDF) in the workplace is common worldwide, and occupation is an important global contributor to the burden of respiratory disease ([@bib1]). For asthma and COPD, the contribution of workplace exposures has been a particular focus of attention in previous American Thoracic Society (ATS) policy statements ([@bib2]--[@bib4]). Occupational exposures also contribute to the disease burden in a number of other conditions, including interstitial disease diagnosed as IPF, HP, other noninfectious granulomatous lung diseases such as sarcoidosis, other interstitial lung diseases, and selected respiratory infections ([@bib5]--[@bib9]).

We synthesized data from multiple sources to quantify the occupational contribution to the burden of nonmalignant respiratory disease. The occupational burden in thoracic cancer (lung and pleura) has been well characterized elsewhere ([@bib10]--[@bib12]). Of note, the classic pneumoconioses (including silicosis, coal workers' pneumoconiosis, and asbestosis) remain an important, unabating global health problem that is not addressed in this document because the occupational contribution to these conditions is essentially 100%. That does not detract, however, from their public health importance.

In this statement, we assess the occupational burden in four categories of respiratory conditions: airway disease (asthma, COPD, and chronic bronchitis), interstitial lung disease (IPF as well as PAP and other uncommon interstitial diseases), granulomatous processes (HP and other noninfectious granulomatous diseases, including sarcoidosis), and selected respiratory infections (tuberculosis \[TB\] and CAP).

Methods
=======

We searched the PubMed and Embase databases from their respective start dates through December 31, 2017, unless otherwise noted. A supplemental literature search was conducted covering January to September 2018. The search strategies, including start dates, rationale, and search terms, are shown in Table E1 in the online supplement. For asthma, COPD, and chronic bronchitis, searches took into account the previous ATS reports ([@bib2]--[@bib4]) and additional reviews ([@bib13]--[@bib20]). We also reviewed reference citations in identified publications to identify relevant papers. Except when stated explicitly, all data were population based and were not limited to a specific industry or exposure. For asthma, COPD, chronic bronchitis, and IPF, we estimated the occupationally related population attributable fraction (PAF) reported by or derived from case--control and cohort studies. When needed, we calculated the PAF using the odds ratio (OR) and proportion of cases exposed \[PAF = pc(OR − 1)/OR, where pc is the proportion of cases exposed\] ([@bib3]). We limited the analysis of asthma to incident data. For PAP, HP, and sarcoidosis, we extracted data from cases series in which the proportion of occupationally related cases was available. For TB, we used World Health Organization and World Bank databases ([@bib21]--[@bib23]) for data on country-specific general population rates to estimate relative disease incidence by occupation. For CAP, we examined both PAF estimates and, within exposure cohorts, the attributable fraction (AF). We pooled published or derived PAF values (asthma, COPD, chronic bronchitis, and interstitial lung disease) and the occupationally attributable burden (PAP, HP, and sarcoidosis) to obtain weighted summary estimates using the metaproportion command in Stata 14.2 software (StataCorp). We used the exact method to compute the 95% confidence interval (CI) for each pooled estimate. Because we recognized that the heterogeneity among the studies was high, we calculated the pooled PAF or proportion using random effects modeling with case numbers informing the weights. We also estimated statistical heterogeneity using the *I*^2^ statistic, which in each case was consistent with high heterogeneity, as we expected (values not presented). We also calculated the pooled estimate excluding the highest and lowest values in the group, as well as calculating the median of the observed PAF or occupational burden values. For TB and CAP, we did not calculate weighted pooled values, limiting summary data to the median values among the estimates considered. For consistency, we use the term "occupational burden" across the various disease outcomes analyzed, even though in some cases the burden was derived from PAF estimates, whereas in others the burden was derived from attribution in case series, incidence rate ratios (IRRs), or AF within a group.

Occupational Burden of Asthma Incidence
=======================================

Work-related asthma is now the most commonly reported work-related respiratory disorder in many industrialized countries. Work-related asthma comprises occupational asthma, defined as asthma "caused" by the workplace, and work-exacerbated (or aggravated) asthma, meaning preexisting asthma with work-related worsening ([@bib24]). Cross-sectional (prevalence) studies have dominated previous estimates of the occupational burden of disease. To build on earlier estimates, we limited our search to longitudinal, population-based studies that reported incident asthma and occupational risk factors.

We identified nine studies with longitudinal data relevant to occupation and incident asthma for inclusion ([@bib25]--[@bib33]) ([Table 1](#tbl1){ref-type="table"}). Of these, six had been included in a previous review ([@bib20]), including a study of Israeli military recruits (over 95% of the Jewish male population aged 18 yr) exposed across a range of vocations ([@bib30]). Three newer studies have been published since the previous review ([@bib20]). One study investigating asthma incidence among persons aged 13--44 years in Tasmania (Australia) reported a high cumulative incidence of asthma (37%) with a work-related job exposure matrix (JEM)-based PAF of 10% ([@bib26]). A second study, using the RHINE (Respiratory Health in Northern Europe) adult study population aged 20--44 years, estimated a JEM-based PAF for occupation of 14% for males and 7% for females ([@bib28]). A later reanalysis using a different JEM arrived at similar estimates (13% and 8% for males and females, respectively) ([@bib34]). A third longitudinal study analyzed data from the United Kingdom. 1958 birth cohort limited to those without asthma by age 16 with later follow-up through age 42 ([@bib29]). Using a JEM to assess exposure risk, the overall occupational PAF was 16%, with wide confidence intervals (95% CI, 3.8--27.1%).

###### 

Longitudinal Population-based Studies of Occupational Risk for Asthma

  First Author, Year, Location (Reference)                                   Study Type                                  Incident Cases (*n* \[Total Population\])                     Definition of Exposure                  PAF (*%*)
  --------------------------------------------- --------------------------------------------------------------------- ------------------------------------------------ ------------------------------------------------------ -----------
  Katz, 1999, Israel ([@bib30])                            Population follow-up ages 18--21 yr at baseline                              588 (59,058)                    Military exposure combat or maintenance vs. clerical      44
  Karjalainen, 2001, Finland ([@bib31])                    Population follow-up ages 25--59 yr at baseline                           49,575 (1,852,848)                              Work-related compensation                    22
  Eagan, 2002, Norway ([@bib25])                           Population follow-up ages 15--70 yr at baseline                              101 (2,723)                       Self-reported dust and fume exposure at baseline        14
  LeVan, 2006, Singapore ([@bib27])                        Population follow-up ages 13--44 yr at baseline                             1,426 (52,325)                      Occupations exposed to dust, smoke, or vapors          8.6
  Kogevinas, 2007, international ([@bib32])                Population follow-up ages 20--44 yr at baseline                              133 (6,837)                           Exposure to high-risk substances by JEM             11
  Hedlund, 2006, Sweden ([@bib33])               Population follow-up ages 36--37, 50--52, and 66--67 yr at baseline                    271 (5,933)                          Blue collar industrial workers vs. others             9
  Lillienberg, 2013, international ([@bib28])    Population follow-up in RHINE population ages 20--44 yr at baseline                 129 males (5,933)                        Exposure to high-risk substances by JEM             14
  286 females (6,253)                                                             7                                                                                                                                           
  Hoy, 2013, Australia (Tasmania) ([@bib26])               Population follow-up ages 13--44 yr at baseline              290 (792[\*](#tblfn1){ref-type="table-fn"})           Exposure to high-risk substances by JEM             10
  Ghosh, 2013, UK ([@bib29])                            Population follow-up of birth cohort up to age 42 yr           611 (7,088[^†^](#tblfn2){ref-type="table-fn"})                    Any asthma JEM \>0                      16.3

*Definition of abbreviations*: JEM = job exposure matrix; PAF = population attributable fraction; RHINE = Respiratory Health in Northern Europe; UK = United Kingdom.

The pooled estimated PAF for the occupational contribution to incident asthma was 16% (95% confidence interval, 10--22%).

Subjects with asthma at baseline excluded.

Total before subjects with childhood asthma were excluded.

Pooling data from all nine studies yielded an estimated PAF for the occupational contribution to incident asthma of 16% (95% CI, 10--22%) ([Figure 1](#fig1){ref-type="fig"}), which is comparable to prior estimates ([@bib2]). Overall, longitudinal data from which inferences can be drawn on the occupational burden of incident asthma are limited. Of note, the studies considered were largely done in developed economic settings. Sex-stratified longitudinal data are even more limited; we identified only two such analyses, both with lower PAF estimates for women than for men.

![Asthma: population attributable fraction (PAF). Forest plot of studies relevant to estimating the occupational contribution to asthma. The estimated PAF, confidence interval (CI), and weighted contribution for each study, as well as the calculated pooled estimate (red dashed line) and 95% CI, are shown. For asthma, the pooled PAF for work exposures is 16% (95% CI, 10--22%). ES = effect size.](rccm.201904-0717ST_f1){#fig1}

Occupational Burden of COPD and Chronic Bronchitis
==================================================

Seven reviews published since the 2003 ATS statement ([@bib3], [@bib13]--[@bib16], [@bib18], [@bib19]) identified 33 papers relating to the occupational contribution to COPD or chronic bronchitis. Of note, two of these found a median PAF for the occupational contribution to COPD of 15% ([@bib13], [@bib15]); one meta-analysis estimated a pooled OR of 1.43 for COPD related to VGDF exposures ([@bib18]), whereas another meta-analysis observed minimal excess risks (1.04--1.15) for separate JEM-defined exposures ([@bib16]). The additional literature search for publications published between 2014 and 2017 identified a further 15 relevant citations not among the 33 included in the reviews noted above.

We retained population-based studies that included a range of potential occupations or case--control studies that clearly reflected the general population. Studies were excluded if they lacked a clear definition of the disease endpoint (e.g., either COPD or chronic bronchitis) or when key data were missing (e.g., studies not presenting the number of subjects exposed that would have allowed for a PAF calculation). When a study reported multiple endpoints or measures of exposure, we preferentially considered risk estimates for COPD defined by spirometry (using lower limit of normal, if reported) over self-reported COPD, and, similarly, we considered JEM-defined risk over self-reported exposure. In studies stratified by smoking status, the ever-smoking stratum was the one used in the pooled analysis of PAF. When data from a never-smoking stratum were available (in some cases the entire cohort analyzed), we used these in a separate pooled analysis of PAF among never-smokers. Results presented only in a stratified manner (e.g., by sex) were considered as separate estimates of risk.

We included 26 studies to estimate the contribution of occupational exposures to the burden of COPD ([@bib35]--[@bib60]) and 7 for the contribution to chronic bronchitis ([@bib39], [@bib40], [@bib50], [@bib51], [@bib61]--[@bib63]). [Table 2](#tbl2){ref-type="table"} summarizes the 26 COPD studies considered, including 28 estimates of risk (taking into account sex-stratified data). The pooled PAF for the occupational contribution to the burden of COPD (including cohorts with mixed smoking status, adjusted for smoking) was 14% (95% CI, 10--18%) ([Figure 2](#fig2){ref-type="fig"}). The occupational PAF for COPD among never-smokers (not shown in table), estimated from six studies including stratified data ([@bib35], [@bib47], [@bib51], [@bib64]--[@bib66]), yielded a pooled PAF of 31% (95% CI, 18--43%).

###### 

Population-based Studies of Occupational Risk for Chronic Obstructive Pulmonary Disease

  First Author, Year, Location (Reference)               Study Type and Population                             Total (*N*)                           Number of Cases                                      Definition of COPD                                             Exposure Information                                  PAF (*%*)
  ------------------------------------------ -------------------------------------------------- ----------------------------------------- -------------------------------------- -------------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------
  Hnizdo, 2002, USA ([@bib35])                                Population based                                    9,823                                    693                            COPD = FEV~1~/FVC \<0.7 and FEV~1~ \<80% (pre-BD)                              Occupational groups                                      19.6
  Trupin, 2003, USA ([@bib36])                                Population based                                    1,932                                    377                                     Self-reported doctor's diagnosis                                         Self-reported                                         20.0
  de Marco, 2004, international ([@bib37])                    Population based                                   14,318                                   1,751                                    COPD = FEV~1~/FVC \<0.7 (pre-BD)                         Self-reported exposure to dust, gas, and fumes                        17.4
  Lindberg, 2005 Sweden ([@bib38])                    Population based (longitudinal)                             1,109                                     83                            COPD = FEV~1~/FVC \<0.7 and FEV~1~ \<80% (pre-BD)            Socioeconomic classification (manual worker in industry)                   15.0
  Sunyer, 2005, international ([@bib39])          Population based (longitudinal), females                        3,279                                     53                                     COPD = FEV~1~/FVC \<0.7 (pre-BD)                                  VGDF by JEM (high exposure)                                  1.0
  Sunyer, 2005, international ([@bib39])           Population based (longitudinal), males                         3,202                                     61                                     COPD = FEV~1~/FVC \<0.7 (pre-BD)                                  VGDF by JEM (high exposure)                                   0
  Jaén, 2006, Spain ([@bib40])                                Population based                                     497                                      73                                    COPD = FEV~1~/FVC \<0.7 (post-BD)                      Self-reported (any exposure to dust, gas, and fumes)                     9.0
  Zhong, 2007, China ([@bib41])                               Population based                                   20,245                                   1,668                                   COPD = FEV~1~/FVC \<0.7 (post-BD)                      Self-reported (any exposure to dust, gas, and fumes)                     3.9
  Weinmann, 2008, USA ([@bib42])                               Case--control                                       744                                     388                               COPD = FEV~1~/FVC below LLN or by algorithm                                         JEM                                               24
  Blanc, 2009, USA ([@bib43])                                  Case--control                                      1,504                                   1,202                                    COPD = FEV~1~/FVC \<0.7 (pre-BD)                                  VGDF by JEM (high exposure)                                  14.0
  Blanc, 2009, USA ([@bib44])                                  Case--control                                      1,788                                     79                                         COPD = FEV~1~/FVC \<0.7                                            VGDF self-reported                                      17.0
  Melville, 2010, UK ([@bib45])                               Population based                                     841                                      84                            COPD = FEV~1~/FVC \<70 and FEV~1~ \<80% (post-BD)              Self-reported occupational exposure at risk of COPD                      50.0
  Idolor, 2011, Philippines ([@bib46])                        Population based                                     722                                     141                                     COPD = FEV~1~/FVC \<70 (post-BD)                             Self-reported exposure in a dusty job                             5.2
  Mehta, 2012, Switzerland ([@bib47])                 Population based (longitudinal)            1,958[\*](#tblfn3){ref-type="table-fn"}   43[\*](#tblfn3){ref-type="table-fn"}             COPD = FEV~1~/FVC below LLN stage II+ (pre-BD)                           VGDF by JEM (high exposure)                  23[\*](#tblfn3){ref-type="table-fn"}
  Lam, 2012, China ([@bib48])                                 Population based                                    8,216                                    461                                   COPD = FEV~1~/FVC below LLN (pre-BD)                    Self-reported (any exposure to dust, gas, and fumes)                     10.4
  Darby, 2012, UK ([@bib49])                                  Population based                                     571                                     197                                     COPD = FEV~1~/FVC \<70 (pre-BD)                                   Self-reported VGDF exposure                                   20
  Hansell, 2014, New Zealand ([@bib50])                       Population based                                     750                                      83                                   COPD = FEV~1~/FVC below LLN (pre-BD)                                VGDF by JEM (high exposure)                                  2.7
  Doney, 2014, USA ([@bib51])                                 Population based                                    3,508                                    196                        COPD = FEV~1~/FVC below LLN and FEV~1~ below LLN (pre-BD)                    Self-reported (severe exposure)                                38.8
  de Jong, 2014, Netherlands ([@bib52])             Population based (LifeLine cohort),                          11,851                                   1,754                                    COPD = FEV~1~/FVC \<0.7 (pre-BD)                                  VGDF by JEM (high exposure)                                  4.3
  de Jong, 2014, Netherlands ([@bib52])       Population based (Vlagtwedde-Vlaardingen cohort)                    2,364                                    639                                     COPD = FEV~1~/FVC \<0.7 (pre-BD)                                  VGDF by JEM (high exposure)                                  9.7
  Pallasaho, 2014, Finland ([@bib53])                 Population based (longitudinal)                             4,080                                    140                                              Self-reported                                                   Self-reported                                         23.6
  Scholes, 2014, UK ([@bib54])                                Population based                                    7,603                                   1,032                                  COPD = FEV~1~/FVC below LLN (pre-BD)                          Job classification as routine occupation                           9.1
  Paulin, 2015, USA ([@bib55])                       Population-based cohort of smokers                           1,075                                    721                                    COPD = FEV~1~/FVC \<0.7 (post-BD)                              VGDF by JEM (intermediate/high risk)                             12.0
  Würtz, 2015, Denmark ([@bib56])                             Population based                                    4,132                                    279                                   COPD = FEV~1~/FVC below LLN (pre-BD)                                VGDF by JEM (high exposure)                                  10.3
  Obaseki, 2016, Nigeria ([@bib57])                           Population based                                     875                                      67                                  COPD = FEV~1~/FVC below LLN (post-BD)                                 Self-reported (dusty jobs)                                  14.9
  Tagiyeva, 2017, UK ([@bib58])                               Population based                                     237                                      63                                  COPD = FEV~1~/FVC below LLN (post-BD)                                        VGDF by JEM                                           0
  Sinha, 2017, India ([@bib59])                               Population based                                    1,203                                    122                                    COPD = FEV~1~/FVC \<0.7 (post-BD)                                         Self-reported                                         34.6
  Torén, 2017, Sweden ([@bib60])                              Population based                                    1,052                                     50                    COPD = FEV~1~/FVC \<0.7 + dyspnea, wheezing, or chronic bronchitis                        Self-reported                                          37

*Definition of abbreviations*: BD = bronchodilator; COPD = chronic obstructive pulmonary disease; JEM = job exposure matrix; LLN = lower limit of normal; PAF = population attributable fraction; UK = United Kingdom; USA = United States; VGDF = vapors, gas, dust, or fumes.

The pooled PAF for the occupational contribution to COPD was 14% (95% confidence interval, 10--18%). The pooled PAF for the occupational contribution to COPD in nonsmokers (references not in table \[[@bib35], [@bib47], [@bib51], [@bib64]--[@bib66]\]) was 31% (95% confidence interval, 10--18%).

Ever-smokers.

![Chronic obstructive pulmonary disease (COPD): population attributable fraction (PAF). Forest plot of studies relevant to estimating the occupational contribution to COPD. The estimated PAF, confidence interval (CI), and weighted contribution for each study are shown, as well as the calculated pooled estimate (red dashed line) and 95% CI. For COPD, the pooled PAF for work exposures is 14% (95% CI, 10--18%). ES = effect size.](rccm.201904-0717ST_f2){#fig2}

[Table 3](#tbl3){ref-type="table"} summarizes the seven chronic bronchitis studies used (eight estimates of risk). The pooled PAF for chronic bronchitis was 13% (95% CI, 6--21%) ([Figure 3](#fig3){ref-type="fig"}). Only two studies allowed estimation of the occupational PAF for chronic bronchitis among never-smokers, yielding values of 8.3% ([@bib51]) and 12% ([@bib67]). Several publications excluded from the tables nonetheless warrant mention. Accelerated annual decline in FEV~1~ in males with early COPD was observed in association with occupational exposures ([@bib68]). An ecological analysis of three large international studies estimated a 0.8% increase in COPD prevalence per 10% increase in occupational exposures, taking into account the concomitant prevalence of smoking ([@bib43]). Several large population-based studies have addressed the association between various occupations and COPD ([@bib11], [@bib69], [@bib70]). Also of note, other researchers have investigated large occupational cohorts, including construction workers exposed to dust ([@bib71], [@bib72]).

###### 

Population-based Studies of Occupational Risk for Chronic Bronchitis

  First Author, Year, Location (Reference)           Study Type and Population           Total (*N*)   Cases (*n*)              Exposure               PAF (*%*)
  ------------------------------------------ ------------------------------------------ ------------- ------------- --------------------------------- -----------
  Montnémery, 2001, Sweden ([@bib61])                     Population based                  8,469          390                Self-reported              11.0
  Lange, 2003, Denmark ([@bib62])                         Population based                  3,736          602                Self-reported              16.0
  Sunyer, 2005, international ([@bib39])       Population based (longitudinal), males       3,951          273                 VGDF by JEM               15.0
  Sunyer, 2005, international ([@bib39])      Population based (longitudinal), females      4,312          250                 VGDF by JEM                0.0
  Jaén, 2006, Spain ([@bib40])                            Population based                   576           69                 Self-reported              29.4
  Doney, 2014, USA ([@bib51])                             Population based                  3,508          280       Self-reported (severe exposure)     23.1
  Hansell, 2014, New Zealand ([@bib50])                   Population based                  1,017          86              JEM (high exposure)           13.1
  Axelsson, 2016, Sweden ([@bib63])                       Population based                  1,172          84                 Self-reported               8.6

*Definition of abbreviations*: JEM = job exposure matrix; PAF = population attributable fraction; USA = United States; VGDF = vapors, gas, dust, or fumes.

The pooled PAF for the occupational contribution to chronic bronchitis was 13% (95% confidence interval, 6--21%).

![Chronic bronchitis: population attributable fraction (PAF). Forest plot of studies relevant to estimating the occupational contribution to chronic bronchitis. The estimated PAF, confidence interval (CI), and weighted contribution for each study are shown, as well as the calculated pooled estimate (red dashed line) and 95% CI. For chronic bronchitis, the pooled PAF for work exposures is 13% (95% CI, 6--21%). ES = effect size.](rccm.201904-0717ST_f3){#fig3}

In summary, an impressive body of new data on the occupational burden of COPD, and to a lesser degree chronic bronchitis, has been published since the original 2003 ATS statement. In aggregate, participant numbers are large and international in scope. The pooled estimates of the occupational PAF of 14% for COPD and 13% for chronic bronchitis are in line with those of the previous ATS statement and interval reviews. Moreover, the higher occupational PAF for COPD among never-smokers (31%) suggests that occupational exposures contribute more substantially to the burden of COPD in nonsmokers.

Occupational Burden of IPF
==========================

IPF is a diagnosis of exclusion made in the presence of a usual interstitial pneumonia pattern on biopsy or with a consistent appearance on a high-resolution computed tomographic scan. The IPF diagnosis presumes that known causes of interstitial lung disease have been excluded (e.g., drug toxicity; connective tissue disease; and domestic, occupational, or environmental exposures) ([@bib73]). Therefore, studies of cohorts with a diagnosis of IPF presumably already exclude persons with a recognized occupational cause of fibrosis, such as asbestosis.

We identified four reviews of occupational exposures in IPF ([@bib5], [@bib74]--[@bib76]) that collectively included 10 relevant case--control studies. One of these, a meta-analysis of six studies, reported a PAF for several exposure categories ranging from 3.5% (silica) to 20% (agriculture) ([@bib5]). Adding more recent citations (*n* = 5), we identified a total of 15 relevant case--control studies addressing the question of occupational exposures associated with IPF ([@bib77]--[@bib91]). Four of the 15 publications were not included in our PAF estimates: one because data were not available on the proportion of cases with specific occupational exposures ([@bib78]), two because of methodological issues in exposure assignment ([@bib85], [@bib86]), and one because of overlap with an included study ([@bib90]). We initially included one publication that appeared in abstract form only ([@bib92]), because we were aware that the full paper was forthcoming ([@bib89]). The remaining 11 case--control studies provided data permitting analysis of occupational exposures in five exposure categories: VGDF, metal dust, wood dust, silica dust, and agricultural dust. For the IPF analysis, VGDF represents an inclusive category combining any of multiple exposures, defined variously by each study.

Thirty-nine risk estimates from 11 studies (1,229 IPF cases in total) contributed to these pooled PAF estimates ([Table 4](#tbl4){ref-type="table"}) ([@bib77], [@bib79]--[@bib84], [@bib87], [@bib88], [@bib91], [@bib92]). The burden of each pooled exposure type was based on 5--11 individual risk estimates ([Table 5](#tbl5){ref-type="table"}). The pooled OR for agricultural work (five studies) was elevated but not statistically significant (OR, 1.6; 95% CI, 0.8--3.0), with a PAF of 4%. The pooled ORs for each of the remaining exposure categories were elevated and statistically significant. These pooled PAFs were as follows: silica (3%), wood dusts (4%), metal dusts or fumes (8%), and VGDF (26%). A forest plot for the estimates for VGDF, the broadest exposure category, is presented in [Figure 4](#fig4){ref-type="fig"}.

###### 

Case-Referent Studies of Occupational Risk Factors for Idiopathic Pulmonary Fibrosis

  First Author, Year, Location (Reference)    Cases (*N*)      IPF Case Definition Criteria         OR (95% CI)        PAF (*%*)                                                                                           
  ------------------------------------------ ------------- ------------------------------------- ----------------- ------------------ ---------------------------- ----------------- ----------------- ---- ---- ---- ---- ----
  Scott, 1990, UK ([@bib77])                      40                Clinical, CXR, PFT            1.3 (0.8--2.0)    11.0 (2.3--52.4)         2.9 (0.9--9.9)         10.9 (1.2--96)    1.6 (0.5--4.8)    17   12   10   12   5
  Hubbard, 1996, UK ([@bib79])                    218             Clinical, CXR, CT, PFT                NA           1.7 (1.1--2.7)          1.7 (1.0--2.9)               NA                NA          NA   10   6    NA   NA
  Mullen, 1998, USA ([@bib80])                    15             Clinical, lung biopsy, CT        2.4 (0.7--8.4)           NA               3.3 (0.4--25.8)               NA          11.0 (1.1--115)   20   NA   7    NA   20
  Baumgartner, 2000, USA ([@bib81])               248              Clinical, biopsy, CT                 NA           2.0 (1.0--4.0)          1.6 (0.8--3.3)         1.6 (1.0--2.5)    3.9 (1.2--12.7)   NA   5    3    7    2
  Hubbard, 2000, UK ([@bib82])                    22                 Death certificate                  NA           1.1 (0.4--2.7)                NA                     NA                NA          NA   5    NA   NA   NA
  Miyake, 2005, Japan ([@bib83])                  102              Lung biopsy, BAL, CT           5.6 (2.1--17.9)   9.6 (1.7--181.1)         6 (0.3--112.4)               NA          1.8 (0.5--7.0)    26   11   4    NA   5
  Gustafson, 2007, Sweden ([@bib84])              140       Pulmonary fibrosis requiring tissue   1.1 (0.7--1.7)     0.9 (0.5--1.6)          1.2 (0.7--2.2)               NA          1.4 (0.7--2.7)    6    NA   3    NA   3
  García-Sancho, 2011, Mexico ([@bib87])          100            Clinical, CT, lung biopsy        2.8 (1.5--5.5)           NA                      NA                     NA                NA          50   NA   NA   NA   NA
  Awadalla, 2012, Egypt (Men) ([@bib88])          95                 Clinical, CT, PFT                  NA           1.6 (0.7--3.6)          2.7 (1.1--6.8)         1.0 (0.4--2.3)    1.1 (0.5--2.7)    NA   6    9    NA   1
  Awadalla, 2012, Egypt (Women) ([@bib88])        106                Clinical, CT, PFT                  NA                 NA               4.3 (0.8--22.1)         3.3 (1.2--10.1)         NA          NA   NA   6    14   NA
  Paolocci, 2013, Italy ([@bib92])                65                   Clinical, CT                     NA           2.8 (1.1--7.2)    1.1 (0.4--3.3) (soft wood)         NA          2.0 (0.9--4.4)    NA   9    0    NA   11
  0.9 (0.3--2.8) (hard wood)                       0                                                                                                                                                                       
  Koo, 2017, Korea ([@bib91])                     78                   Clinical, CT               2.7 (0.7--10.9)   5.0 (1.4--18.2)         2.5 (0.5--12.4)               NA          1.2 (0.4--3.8)    35   22   5    NA   5

*Definition* *of abbreviations*: Ag = agricultural dusts; CI = confidence interval; CT = computed tomography; CXR = chest radiograph; IPF = idiopathic pulmonary fibrosis; NA = not applicable; OR = odds ratio; PAF = population attributable fraction; PFT = pulmonary function test; UK = United Kingdom; USA = United States; VGDF = vapors, gas, dust, or fumes, which represent all the exposure categories shown combined and, in selected studies, additional exposures as well.

All studies had case--control designs, with most by interview-based self-reported exposure assessment (Hubbard exposure by job category). Awadalla and colleagues stratified their study sample by male (*n* = 95) and female (*n* =  106). The study by Paolocci and colleagues, which estimated risk with two separate wood variables, later appeared as a full publication ([@bib89]).

###### 

Pooled Population Attributable Fraction Estimates for Occupation and Idiopathic Pulmonary Fibrosis

  Exposure              Risk Estimates (*N*)   Pooled OR (95% CI)   Pooled PAF (*%*) (95% CI)
  -------------------- ---------------------- -------------------- ---------------------------
  VGDF                           6               2.0 (1.2--3.2)            26 (10--41)
  Metal dusts                    9               2.0 (1.3--3.0)             8 (4--13)
  Wood dusts                     11              1.7 (1.3--2.2)             4 (2--6)
  Agricultural dusts             5               1.6 (0.8--3.0)             4 (0--12)
  Silica                         8               1.7 (1.2--2.4)             3 (2--5)

*Definition of abbreviations*: CI = confidence interval; OR = odds ratio; PAF = population attributable fraction; VGDF = vapors, gas, dust, or fumes, which represent all the other exposure categories shown combined and, in selected studies, additional exposures as well.

![Idiopathic pulmonary fibrosis (IPF): population attributable fraction (PAF) from vapors, gas, dust, or fumes (VGDF). Forest plot of studies relevant to estimating the occupational contribution to IPF of VGDF (combined categories of exposure considered in the studies included). The estimated PAF, confidence interval (CI), and weighted contribution for each study are shown, as well as the calculated pooled estimate (red dashed line) and 95% CI. For IPF, the pooled PAF for VGDF is 26% (95% CI, 10--41%). ES = effect size.](rccm.201904-0717ST_f4){#fig4}

In summary, our findings suggest that occupational exposures contribute substantially to the burden of disease otherwise considered idiopathic and labeled "IPF." It is also interesting to note that in one Korean study, patients with IPF who had been occupationally exposed to dust had earlier onset of disease and worse prognosis ([@bib93]). A major challenge in assessing the occupational burden of IPF disease is differentiating between disease misclassification (e.g., chronic HP or one of the classic pneumoconioses \[e.g., asbestosis, silicosis\] misdiagnosed as IPF) and a causative role of work exposures in usual interstitial pneumonia--like processes. Another important challenge is exposure misclassification, especially when estimating chronic inhalational work exposures over many years. For example, asbestos exposure was common in metal and wood industries and could have contributed to these exposure-associated PAFs for IPF.

Occupational Burden of PAP and Other Interstitial Lung Diseases
===============================================================

PAP has been categorized as primary (idiopathic), secondary, or congenital ([@bib94], [@bib95]). Primary PAP involves autoantibodies to granulocyte--macrophage colony--stimulating factor ([@bib94]); secondary PAP is attributed to a variety of occupational exposures, most notably silica ([@bib96]--[@bib108]). Cases of autoimmune PAP have been reported in occupationally exposed persons ([@bib98], [@bib99], [@bib109]--[@bib111]).

We included 29 relevant publications since 1958 subsuming 1,539 PAP cases (with a range of 10--241 cases per series) ([@bib112]--[@bib140]), excluding overlapping reports ([@bib141]--[@bib144]). The reported occupational exposure prevalence ranged from 0% to 67%, with a pooled prevalence of 29% (95% CI, 21--37%) ([Table 6](#tbl6){ref-type="table"}). A range of exposures was reported, including vapors or gases (cleaning fluids, gasoline, hairspray, paint, and pesticides), inorganic dusts (asbestos, cement, chalk, coal, glass fiber, and silica), organic dusts (cotton, flour, wood, and wool), and metal dusts or fumes (aluminum, copper, indium, iron, and zirconium). Among 19 publications that specifically reported on silica (786 PAP cases), the exposure prevalence ranged from 0% to 22%, with pooled prevalence of 5% (95% CI, 2--8%) ([@bib112], [@bib114]--[@bib120], [@bib124]--[@bib127], [@bib129], [@bib133], [@bib135]--[@bib137], [@bib139], [@bib140]). Among the five publications describing 345 autoimmune PAP cases, occupational exposure prevalence ranged from 26% to 55% ([@bib121], [@bib132], [@bib133], [@bib139], [@bib141]).

###### 

Occupational Exposures in Pulmonary Alveolar Proteinosis

  First Author, Year, Location (Reference)       Exposure Measure      Cases (*N*)   Occupational Burden (*%*)
  ------------------------------------------- ----------------------- ------------- ---------------------------
  Davidson,1969, international ([@bib112])       Reported history          139                  50
  McEuen, 1978, USA ([@bib113])                Lung tissue particles       37                   35
  Rubin, 1980, Canada ([@bib114])                Reported history          13                   15
  Kariman, 1984, USA ([@bib115])                 Reported history          23                    0
  Prakash, 1987, USA ([@bib116])                 Reported history          34                    9
  Asamoto, 1995, Japan ([@bib117])               Reported history          68                   15
  Goldstein, 1998, USA ([@bib118])               Reported history          24                   50
  Kim, 1999, Korea ([@bib119])                   Reported history          10                   40
  Briens, 2002, France, Belgium ([@bib120])        Questionnaire           41                   39
  Inoue, 2008, Japan ([@bib121])                   Questionnaire           199                  26
  Fang, 2009, China ([@bib122])                  Reported history          11                   18
  Xu, 2009, China ([@bib123])                    Reported history          241                   8
  Byun, 2010, Korea ([@bib124])                  Reported history          38                    0
  Bonella, 2011, Germany ([@bib125])               Questionnaire           70                   51
  Fang, 2012, China ([@bib126])                  Reported history          25                   36
  Campo, 2013, Italy ([@bib127])                 Reported history          73                   36
  Zhao, 2013, China ([@bib128])                  Reported history          30                   67
  Fijołek, 2014, Poland ([@bib129])              Reported history          17                   24
  Ilkovich, 2014, Russia ([@bib130])             Reported history          68                   59
  Yang, 2014, China ([@bib131])                  Reported history          10                   20
  Akasaka, 2015, Japan ([@bib132])               Reported history          31                   26
  Xiao, 2015, China ([@bib133])                    Questionnaire           45                   38
  Bai, 2016, China ([@bib134])                     Questionnaire           101                  50
  Deleanu, 2016, Romania ([@bib135])             Reported history          20                   20
  Hadda, 2016, India ([@bib136])                 Reported history          35                   14
  Huang, 2016, China ([@bib137])                 Reported history          17                   29
  Mo, 2016, China ([@bib138])                    Reported history          11                   18
  Guo, 2017, China ([@bib139])                   Reported history          37                   49
  Hwang, 2017, Korea ([@bib140])                 Reported history          71                   48

*Definition of abbreviation*: USA = United States.

All studies are case series except four case--control studies ([@bib113], [@bib126], [@bib133], [@bib158]) and one national registry ([@bib121]). "Reported history" refers to occupational or exposure history from the clinical record. Occupational burden is based on the prevalence among cases of occupations likely to involve inhalational exposures or inhalational exposures likely to be occupational. The pooled occupational burden was 29% (95% confidence interval, 21--37%).

Although PAP has a more robust literature relevant to the occupational burden of disease, there are a number of other respiratory syndromes in which occupational associations have been observed in disease outbreaks, in certain work settings, or after suspect exposures ([@bib142], [@bib145]--[@bib161]). Table E2 provides selected examples of these reported associations, which include bronchiolitis and the flavoring chemical diacetyl; cryptogenic organizing pneumonia and textile dye ("Ardystil syndrome"); and diffuse pulmonary hemorrhage and trimellitic anhydride ([@bib142], [@bib145]--[@bib161]).

Occupational Burden of HP (Extrinsic Allergic Alveolitis) and Other Granulomatous Lung Diseases, Including Sarcoidosis
======================================================================================================================

We synthesized data from 15 relevant publications for HP, the earliest paper dating from 1983 (*see* [Table 7](#tbl7){ref-type="table"}). We excluded case series limited to a single avocation or occupation (e.g., bird fanciers or machinists) ([@bib162], [@bib163]), if there were insufficient data to determine the proportion due to an occupational exposure ([@bib164]), or if there were overlapping cases ([@bib165]) that were included in another publication ([@bib166]). The studies included ([@bib166]--[@bib180]) were all case series (or registries), except for one case--control design ([@bib167]), but used variable criteria for diagnosing HP and assessing causation. For the case series, we considered the work-related cases within a larger series to represent the occupational burden of disease. The estimated occupational burden of disease ([Figure 5](#fig5){ref-type="fig"}) ranged from 0% to 81.3%, with a weighted metaproportion of 19% (95% CI, 12--28%).

###### 

Occupational Associations with Hypersensitivity Pneumonitis

  First Author, Year, Location (Reference)                 Study Type                Cases (*N*)                                             Disease Definition                                                                                 Exposure/Job Information                                                                       Comments                                  Occupational Burden (*%*)
  ------------------------------------------ -------------------------------------- ------------- -------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ---------------------------
  Kawanami, 1983, USA ([@bib168])                         Case series                    18                               Clinical, radiographic, physiologic, and laboratory data                                            History, clinical data, and serologic testing in 13 patients                                     72.2% environmental; 27.7% unknown cause                              0
  Yoshida, 1995, Japan ([@bib169])                        Case series                    835       Criteria of the Japan Research Committee on Diffuse Pulmonary Disease for Hypersensitivity Pneumonitis                             History, clinical data, and serologic testing                                            79.4% environmental; 6.8% unknown cause                             13.8
  Yoshizawa, 1999, Japan ([@bib170])                      Case series                    36                                            Clinical and imaging criteria                                                                  History, clinical data, and serologic testing                             61.4% environmental; 13.9% unknown cause, series limited to chronic HP             25.3
  Thomeer, 2001, Belgium ([@bib171])              Multicenter disease registry           47                 A set of clinical and imaging criteria; data from the nationwide electronic register                                                   Not clearly stated                                                          76.6% environmental; 23.4% unknown cause                              0
  Bang, 2006, USA ([@bib172])                        Death certificate date              814                                              Death certificate coding                                                Occupationally related ICD codes for causes\>100% due to multiple coded causes of HP                         38.4% occupational; 55.6% unknown cause                             40.5
  Hanak, 2007, USA ([@bib173])                  Case series from a single center         85                             Clinical and imaging criteria from the Mayo Clinic database                                                   History, clinical data, and serologic testing                                            64.7% environmental; 24.7% unknown cause                            10.6
  Olson, 2008, USA ([@bib174])                  Case series from a single center          4                     Retrospective case review; only cases with acute exacerbation of fibrotic HP                               History, clinical data, and serologic testing; biopsy confirmation                                    50% environmental; 50% unknown cause                                0
  Selman, 2010, multicountry ([@bib166])      Prospective multicenter cohort study       199                            Clinical and imaging data, supported by the experts' opinion                                                  History, clinical data, and serologic testing                                            76.9% environmental; 1.5% unknown cause                             21.6
  Cımrın, 2010, Turkey ([@bib175])                 Review of published cases             22                                  Based on cases as defined in publications reviewed                                                                       Heterogeneous                                                           66.6% environmental; none of unknown cause                           33.3
  Caillaud, 2012, France ([@bib176])                Case series, multicenter             139                                           Clinical and imaging criteria                                                                  History, clinical data, and serologic testing                                           18.7% environmental; none of unknown cause                           81.3
  Alhamad, 2013, Saudi Arabia ([@bib177])                 Case series                    21                           A set of clinical and imaging criteria followed by expert review                                                                Questionnaire                                                            42.9% environmental; 33.3% unknown cause                            23.8
  Castonguay, 2015, USA ([@bib178])                       Case series                    40                                            Clinical and imaging criteria                                        History, clinical data, and serologic testing; case overlap with Hanak *et al.*, 2007 ([@bib173])                   55% environmental; 37.5% unknown cause                              7.5
  Millerick-May, 2016, USA ([@bib179])                    Case series                    19                                       ATS guidelines for the diagnosis of ILD                                                             History, clinical data, and serologic testing                                           51.9% environmental; none of unknown cause                           42.1
  Singh, 2017, India ([@bib180])                      Prospective registry               513                                         Diagnostic criteria, expert review                                                                               Questionnaire                                                            69.4% environmental; 24.8% unknown cause                             5.8
  Cramer, 2016 Denmark ([@bib167])                 Retrospective cohort study           6,920                        Cases identified from records in Danish National Patient Register                                           Data on occupation were provided by Statistics Denmark                                   OR, 1.55 (95% CI, 1.40--1.72); cases exposed = 46%                       20.2

*Definition of abbreviations*: ATS = American Thoracic Society; CI = confidence interval; HP = hypersensitivity pneumonitis; ICD = International Classification of Diseases; ILD = interstitial lung disease; OR = odds ratio; USA = United States.

Occupational burden is derived from the proportion of occupationally attributed cases in the series or, in the case of Cramer and colleagues ([@bib167]), derived from the OR and proportion of exposed cases. The overall burden of occupationally attributed HP is 19% (95% CI, 12--28%).

![Hypersensitivity pneumonitis (HP): occupational burden. Forest plot of studies relevant to estimating the contribution of work exposures to HP. The occupational prevalence of HP, confidence interval (CI), and weighted contribution for each study are shown, as well as the calculated pooled estimate (red dashed line) and 95% CI. The pooled proportion of occupational HP among all HP cases is 19% (95% CI, 12--28%). ES = effect size.](rccm.201904-0717ST_f5){#fig5}

In addition to HP, we also considered the occupational burden of other noninfectious granulomatous lung diseases. Inhalation of beryllium can cause granulomatous lung disease that mimics sarcoidosis; other metals have also been associated with granulomatous responses; and sarcoidosis prevalence has been reported to be elevated among various occupational groups, including firefighters, navy recruits, workers in the lumber industry, rock or glass wool workers, salespeople, and World Trade Center disaster emergency responders ([@bib181], [@bib182]). Several large case-referent studies of patients with sarcoidosis who were not beryllium sensitized have found that occupational exposures to organic dusts, bioaerosols, and metals increased risk of sarcoidosis ([@bib183]--[@bib185]). A study of sarcoidosis prevalence in Switzerland found higher frequencies in regions with metal industry and intense agriculture ([@bib186]). In a large U.S. study using national death certificate data, sarcoidosis mortality risk was significantly elevated in association with metalworking, health care, teaching, sales, banking, and administration ([@bib181]). Mortality data also suggest that occupational exposures may increase risk for a more severe sarcoidosis phenotype ([@bib187]).

Epidemiological evidence on the proportion of chronic beryllium disease misdiagnosed as sarcoidosis is limited to a few case series ([@bib188]--[@bib192]) and one case-referent study ([@bib193]). Combining beryllium-focused studies of sarcoidosis with other studies that estimated occupational risk, we identified seven studies to use to estimate the occupational burden of sarcoidosis ([Table 8](#tbl8){ref-type="table"}) ([@bib181], [@bib183], [@bib184], [@bib188]--[@bib190], [@bib193]). The pooled estimated occupational proportion of sarcoidosis ranged from 0% to 54%, with a weighted metaproportion of 30% (95% CI, 17--45%).

###### 

Occupational Proportion of Granulomatous Disease Diagnosed as Sarcoidosis

  First Author, Year, Location (Reference)               Study Type           Cases (*N*)                                                  Disease Definition                                                                               Exposure/Job Information                                                           Comments                               Occupational Burden (*%*)
  --------------------------------------------- ---------------------------- ------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------ ---------------------------
  Fireman, 2003, Israel ([@bib190])                     Case series               47                             Tissue diagnosis with positive beryllium lymphocyte transformation test                                          Possible occupational exposure to beryllium                                   Case series from one outpatient clinic                           6.4
  Kucera, 2003, USA ([@bib185])                    Sibling case--control          303                                 Clinicoradiographic presentation consistent with sarcoidosis                                               Structured occupational history questionnaire                              ACCESS questionnaire for occupational history                        37
  Barnard, 2005, USA ([@bib183])                       Case--control              706                            Tissue diagnosis with negative beryllium lymphocyte proliferation test                                          Structured occupational history questionnaire                     Multicenter study, ACCESS questionnaire for occupational history             51.6
  Müller-Quernheim, 2006, Germany ([@bib189])           Case series               84        Clinicoradiographic presentation consistent with sarcoidosis and positive beryllium lymphocyte proliferation test       Possible occupational exposure to beryllium, determined by questionnaire                         Prospective study over 7 yr                                40.4
  Ribeiro, 2011, Canada ([@bib188])                     Case series               121       Clinicoradiographic presentation consistent with sarcoidosis and positive beryllium lymphocyte proliferation test       Possible occupational exposure to beryllium, determined by questionnaire         No positive beryllium lymphocyte proliferation test results                  0
  Cherry, 2015, Canada ([@bib193])                     Case-referent              63              Medical record review, cases with diagnosis of sarcoidosis, referents with other chronic lung disease         Patient interview, employment in an industry with possible exposure to beryllium      Chronic beryllium disease diagnosis based on Glu69 status                  46
  Liu, 2016, USA ([@bib181])                     Population-based mortality      3,393                            Sarcoidosis death based on cause of death listed on death certificate                                              Usual occupation on death certificate                                              Large national dataset                                  53.8

*Definition of abbreviations*: ACCESS = A Case-Control Etiologic Study of Sarcoidosis; USA = United States.

Occupational burden is derived from the proportion of occupationally attributed cases in series or derived from a reported odds ratio and proportion of exposed cases. The overall burden of occupationally attributed sarcoidosis is 30% (95% confidence interval, 17--45%).

Occupational Burden of TB and CAP
=================================

Certain occupational groups are at increased risk for TB infection or bacterial CAP. The occupational burden of these infectious diseases, however, has been infrequently quantified ([@bib194]--[@bib197]). Searching back to 1990, we identified 9 silica-related and 17 healthcare worker (HCW)-related relevant studies for inclusion in this analysis ([@bib198]--[@bib222]) ([Tables 9](#tbl9){ref-type="table"} and [10](#tbl10){ref-type="table"}). We excluded studies that dealt exclusively with latent TB, did not use diagnostic criteria for TB, or were reviewed in previous analyses (and thus were not included in our estimates) ([@bib195], [@bib223]).

###### 

Tuberculosis among Silica-exposed Workers

  First Author, Year, Location (Reference)           Study Type                                           TB Definition/Diagnosis                                                        Exposure/Job Information                                                               Population Cases (*n*)/Control or Total Population (*N*)                                                  Risk Estimates (95% CI when available)         Occupational Burden (*%*)
  ---------------------------------------------- ------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ---------------------------
  Rosenman, 1996, USA ([@bib209])                   Case--control                                Bacteriological or reporting of treatment                                     SIC and SOC codes used as proxy for exposures          HIV-positive and foreign-born individuals excluded; 149 cases from New Jersey TB Register, 209 control subjects from previous cancer studies   Adjusted OR for silica industries: 1.6 (0.7--3.8)              4.9
  Chen, 1997, USA ([@bib210])                       Case--control                                Death certificate data from NOMS database                                                Silica-exposed workers                                                            8,740 cases: 2% intermediate, 14% high; 83,338 control subjects                                                    OR~intermed~: 1.1 (0.8--1.5)                  Intermediate: 0.2
  OR~high~: 1.3 (1.1--1.5)                            High: 3.2                                                                                                                                                                                                                                                                                                                                                                         
  Calvert, 2003, USA ([@bib211])                    Case--control                                Death certificate data from NOMS database                              Subjects assigned to a qualitative silica exposure category                             6,570 cases: medium (11.7%), high (9.5%), super high (0.6%), 32,843 TB control subjects                                           OR~med~: 1.3 (1.2--1.5)                      Medium: 3.04
  OR~high~: 1.6 (1.5--1.8)                            High: 3.4                                                                                                                                                                                                                                                                                                                                                                         
  OR~super\ high~: 2.5 (1.7--3.7)                  Super high: 3.6                                                                                                                                                                                                                                                                                                                                                                      
  Kleinschmidt, 1997, South Africa ([@bib212])         Cohort                                     Bacteriological and clinical diagnosis                                Gold miners from a single mine, followed from 1975 to 1996                                                    449 cases (total cohort = 4,976 gold miners)                                                                       IRR, 2.5                                   2.3
  Murray, 1999, South Africa ([@bib213])               Cohort                                             Culture-positive sputum                                                       Gold miners from four mines                                                                  376 cases (total cohort = 28,522 gold miners)                                                                       IRR, 4.2                                   4.8
  Churchyard, 2000, South Africa ([@bib214])           Cohort                                     Bacteriological and clinical diagnosis                                  Gold miners at a single mine followed from 1993 to 1997                                                                     2,893 cases                                                                                        IRR, 7.5                                   7.9
  Sonnenberg, 2005, South Africa ([@bib215])           Cohort         Culture-positive "probable TB" = score of radiography, sputum, tuberculin, histology, and trial     Gold miners from four mines followed from 1991 to 1997                                                           747 cases (total cohort = 23,874)                                                                             IRR, 3.9                                   3.8
  Glynn, 2008, South Africa ([@bib216])                Cohort                                          Culture and clinical findings                                      Gold miners from four mines followed from 1991 to 2004                                                         620 new cases among 7,583 participants                                                                          IRR, 4.3                                   2.0
  van Halsema, 2012, South Africa ([@bib217])          Cohort                                                     Culture                                                  Gold miners from two mines followed from 2002 to 2008                                                                4,268 TB/19,476 (mine A)                                                                             IRR, 3.1 (mine A)                          Mine A: 1.1
  1,472 TB/8,414 (mine B)                         IRR, 2.5 (mine B)                                             Mine B: 0.8                                                                                                                                                                                                                                                                                                             

*Definition of abbreviations*: CI = confidence interval; IRR = incidence rate ratio; NOMS = National Occupational Mortality Surveillance; OR = odds ratio; SIC = Standard Industrial Classification; SOC = Standard Occupational Classification; TB = tuberculosis; USA = United States.

Except for publications providing an OR, the occupational burden is estimated from an IRR derived from World Bank and World Health Organization data for the silica-exposed labor force and national TB rates. The median silica-associated burden of TB was 2.3% (range, 0.8--7.9%).

###### 

Tuberculosis among Healthcare Workers

  First Author, Year, Location (Reference)                  Study Type                                    TB Definition/Diagnosis                                                        Exposure/Job Information                                                         Cases (*n*)/Control or Total Population (*N*)                                                 Risk Estimate                           Occupational Burden (*%*)
  --------------------------------------------- ---------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------- ---------------------------
  Rosenman, 1996, USA ([@bib209])                         Case--control                            Bacteriological or treatment reporting                                      SIC and SOC codes used as proxy for exposures                       HIV-positive, foreign-born cases excluded; 149 cases from TB registry; 290 cancer referents                    OR, 2.8 (95% CI, 1.4--5.7)                               8.2
  Raitio, 2000, Finland ([@bib203])                  National register review               Bacteriologically, histologically, and/or clinically                  All HCWs assessed for occupational TB, extracted from national register                                        658 cases between 1966 and 1995                                                          IRR, 0.67                                         0
  Laraqui, 2001, Morocco ([@bib218])                     Cross-sectional                                     Case notification                                          All HCWs notified by health services between 1994 and 1997                                                130 cases among 152,447 HCWs                                                            IRR, 0.72                                         0
  Eyob, 2002, Ethiopia ([@bib204])                            Cohort                        Sputum culture or clinical or radiological findings                                       HCWs at a specialist TB center                                                                 24 cases among 175 HCWs                                              IRR, 7.2[\*](#tblfn4){ref-type="table-fn"}                       0.4
  Jiamjarasrangsi, 2005, Thailand ([@bib198])                 Cohort                              TB diagnoses in medical records database                                        Thai HCWs observed at a single hospital                                                           78 cases among 3,894 HCWs                                                              IRR, 3.5                                        0.1
  Tam, 2006, Hong Kong ([@bib219])               National registry records review                                Not stated                                        Surveillance data of occupational TB reported to the Labor Department                                      141 cases among 57,869 HCWs over 5 yr                                                        IRR, 0.5                                         0
  de Vries, 2006, Netherlands ([@bib200])                 Records review            Restriction fragment length polymorphism typing (DNA fingerprinting)   Cases ''working in the healthcare/social-welfare sector'' from a national TB registry                                   94 cases among 126,500 HCWs                                                             IRR, 0.8                                         0
  Ong, 2006, USA ([@bib201])                               Cohort study                   TB reported to San Francisco Department of Public Health                             All cases of TB reported over multiple years                                              33 cases among HCWs among 2,510 cases reported                                                    IRR, 1.2                                        1.0
  Pazin-Filho, 2008, Brazil ([@bib205])                  Database review                                      Clinical, sputum                                                         HCWs at a university hospital                                                                   21 cases among HCWs                                       IRR, 2.6[\*](#tblfn4){ref-type="table-fn"} nurse technicians              1.4
  Roche, 2008, Australia ([@bib199])                     Database review                            Laboratory, clinical diagnosis of TB                             HCWs recorded in National Notifiable Diseases Surveillance System                                        65 cases among HCWs reported in 2006                                                         IRR, 2.1                                        4.0
  Costa, 2011, Portugal ([@bib206])                           Cohort                              Clinical, bacteriological, radiological                                HCWs at the São João Hospital followed from 2005 to 2010                                                   62 cases among 6,112 HCWs                                                              IRR, 3.2                                        4.4
  Lambert, 2012, USA ([@bib202])                         Database review                     Review of National TB Surveillance System records                                         TB cases reported to the CDC                                                      6,049 cases among HCWs among the 200,774 cases                                                    IRR, 0.8                                         0
  Tudor, 2014, South Africa ([@bib207])                Retrospective cohort                              Based on records captured                                         HCWs in three hospitals with specialist MDR-TB wards                                            112 cases among 1,313 HCW records reviewed                                     IRR, 2.0[\*](#tblfn4){ref-type="table-fn"}                       1.3
  Toms, 2015, Australia ([@bib220])                  National database review                 National Notifiable Diseases Surveillance System                               Working in a healthcare setting in the past 12 mo                                                     24 cases among HCWs in 2013                                                             IRR, 1.1                                        0.1
  Klimuk, 2014, Belarus ([@bib208])                Retrospective record review               Sputum smear, culture, drug susceptibility testing                               Review of records from TB healthcare facilities                                                      116 cases among 5,441 HCWs                                                              IRR, 5.4                                        8.9
  O'Hara, 2017, South Africa ([@bib222])             National database review                          Laboratory-confirmed diagnosis                                        All HCWs in a particular province in South Africa                                        2,677 cases of TB among 32,039 HCWs over 11-yr period                              IRR, 1.14[\*](#tblfn4){ref-type="table-fn"}                       1.2
  Davidson, 2017, UK ([@bib221])                     National TB surveillance                   Notified TB cases from surveillance database                                   HCW work information extracted from database                                                2,320 cases of HCW TB between 2009 and 2013                                    IRR, 1.5[\*](#tblfn4){ref-type="table-fn"}                       2.8

*Definition of abbreviations*: CI = confidence interval; HCW = healthcare worker; IRR = incidence rate ratio; MDR-TB = multidrug-resistant tuberculosis; OR = odds ratio; SIC = Standard Industrial Classification; SOC = Standard Occupational Classification; TB = tuberculosis; UK = United Kingdom; USA = United States.

Except for one publication providing an OR, the occupational burden is estimated from an IRR either reported or derived from World Bank and World Health Organization data for the HCW labor force and national TB rates. The median HCW-associated burden of TB was 1.0% (range, 0.8--9%).

Author-reported IRR.

We considered TB in two distinct occupational risk groups: those exposed occupationally to silica and those exposed as HCWs. For TB among the silica exposed, three U.S. studies and six South African studies allowed estimation of an occupation-associated burden of disease ([@bib209]--[@bib217]). For the U.S. studies, the estimated burden ranged from 3.2% to 4.9%. For the South African studies using gold miner cohorts, the occupational burden was estimated by deriving an IRR for miners relative to national rates of disease; the median silica-associated burden was 2.3% (range, 0.8--7.9%) ([Table 9](#tbl9){ref-type="table"}). One other estimate of the occupational burden from an Iranian study, strikingly higher than all other studies (36%), was omitted because selection bias may have been present ([@bib224]).

As shown in [Table 10](#tbl10){ref-type="table"}, we found little consistency in estimates of the occupational burden of TB in HCWs. In five studies, the incidence rate among HCWs was lower than that of the general population ([@bib200], [@bib202], [@bib203], [@bib218], [@bib219]), yielding an estimated burden of zero. Among those with an appreciable burden (IRR ≥ 1), the occupational burden ranged from 0.1% ([@bib198]) to 8.9% ([@bib198]). In one of these studies ([@bib221]), even though there was an increased TB IRR overall, this was accounted for by foreign-born HCWs, and work-acquired infection was confirmed in only a handful of cases. Based on all 17 HCW studies, the overall median estimate was 1.0% (range, 0--8.9%) ([Table 10](#tbl10){ref-type="table"}). A previous review of TB among HCWs ([@bib195]) reported similar occupational burdens of disease among low-- and high--TB incidence countries.

We identified 15 publications relevant to the occupational burden of CAP. Six were population-based case--control studies estimating CAP risk ([@bib225]--[@bib230]). Of these, the earlier of two overlapping publications from the same Spanish research group was excluded ([@bib225]), as well as the earlier of two related publications from Canada ([@bib226]). The four remaining case-referent studies ([Table 11](#tbl11){ref-type="table"}) yielded a median PAF of 10% (range, 3--45%) for the occupational burden of pneumonia.

###### 

Studies Used to Calculate the Occupational Population Attributable Fraction and Attributable Fraction in Community-acquired Pneumonia

  First Author, Year, Location (Reference)                          Type of Study                                                                        Population/Cases/Control Subjects                                                                                                                       Pneumonia Type/Definition                                                                                                  Exposure Information                                    PAF or AF (*%*)[\*](#tblfn5){ref-type="table-fn"}
  -------------------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------- ---------------------------------------------------
  Occupational PAF of pneumonia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
   Farr, 2000, UK ([@bib227])                                       Case--control                                175 cases from British Thoracic Society study of patients with community-acquired pneumonia; 385 control subjects                                           Acute respiratory infiltrate; *Mycoplasma* excluded; 70% with streptococcal pneumonia confirmation                                                  Self-reported dusty occupation (OR, 1.71)                                                 16
   Palmer, 2003, UK ([@bib228])                                     Case--control                                            525 cases, 1,222 referents aged 20--64 yr; 158 lobar; 142 segmental; 225 bronchopneumonia                                                               New/worse respiratory infection, new chest radiograph opacity, hospital admission                                        Self-reported metal fumes in prior year; OR, 1.6, all; OR, 1.8, lobar pneumonia                             3, 4
   Neupane, 2010, Canada ([@bib230])                                Case--control                                                                   365 cases of pneumonia; 494 control subjects                                                                                            Admission to hospital for pneumonia, temperature \>38°C, new opacity                                                                 Self-reported exposure to VGDF (OR, 5.78)                                                 45
   Almirall, 2015, Spain ([@bib229])                                Case--control                                                                 1,336 cases of pneumonia; 1,326 control subjects                                                                                           Acute respiratory illness, new radiographic findings, antibiotics                                                                    Self-reported exposure to dust (OR, 1.7)                                                  3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Occupational AF of pneumonia in specific cohorts                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Beaumont, 1980, USA ([@bib235])                                 Cohort mortality                                                                   8,679 metal trades union; 3,247 welders                                                                                                                          All pneumonia                                                                                             Job classification based on union records                                                 41
   Newhouse, 1985, UK ([@bib236])                                  Cohort mortality                                                                         1,027 welders at a shipyard                                                                                                                                All pneumonia                                                                             Personnel records from shipyard: job title, tasks; SMR for pneumonia, 269                                 46
   Coggon, 1994, UK ([@bib237])                                    Cohort mortality                                                Male welders England and Wales, 1979--1980 and 1982--1999; 55 pneumonia deaths                                                                                                     Lobar pneumonia                                                                                                      OPCS; welders PMR, 255                                                          62
   Graham, 2004, USA ([@bib233])                                   Cohort mortality                                               5,408 Vermont granite workers; 2,539 deceased, determined by death certificates                                                                                                 All pneumonia, ICD codes                                                                                             Employment records SMR, \<100                                                        0
   Veiga, 2006, Brazil ([@bib234])                                 Cohort mortality                                                                              2,856 coal miners                                                                                                                                     All pneumonia                                                                                        Employment records SMR for pneumonia in miners, 263                                            62
   Palmer, 2009, UK ([@bib238])                                  Population mortality                                                         Occupations with exposure to metal fumes, aged 18--64 yr                                                                                                          Lobar pneumonia, ICD-9 codes                                                                                         OPCS; welders PMR, 242 (166--342)                                                     59
   Wong, 2010 Canada ([@bib239])                              Retrospective chart review                                         1,768 cases of pneumococcal disease; 863 cases aged 18--65 yr; 18 cases in welders                                                                     Invasive pneumococcal disease, positive culture results (blood, CSF, other)                                                         Self-reported current occupation OR for welders, 2.7                                           63
   Koh, 2011, Korea ([@bib231])                                  Retrospective cohort                    Mineral dust-- and metal fume--exposed workers: 365 cases (59 in foundry workers); control group (noise-only exposure), 927 cases                                           All pneumonia (viral, bacterial, fungal), \>1-d hospitalization; SAR for pneumonia                                    National Health Insurance claims, employer, SIC codes; foundry workers SAR, 1.64 (men)                          38
   Torén, 2011, Sweden ([@bib232])                    Prospective cohort of construction workers   183,194 construction workers aged 20--64 yr; followed for 32 yr; 145 deaths resulting from pneumonia, 62 deaths resulting from lobar pneumonia   Mortality of all infectious pneumonia, lobar pneumonia, pneumococcal pneumonia; viral and fungal pneumonia excluded; Swedish Cause of Death Register                                Self-reported job title, JEM                                                         
  Relative risk for all and lobar pneumonias                                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Inorganic dusts                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
    All pneumonia, 1.87                                                   47                                                                                                                                                                                                                                                                                                                                                                                                                       
    Lobar pneumonia, 3.37                                                 70                                                                                                                                                                                                                                                                                                                                                                                                                       
   Metal fumes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
    All pneumonia, 2.31                                                   57                                                                                                                                                                                                                                                                                                                                                                                                                       
    Lobar pneumonia, 3.67                                                 73                                                                                                                                                                                                                                                                                                                                                                                                                       

*Definition of abbreviations*: AF = attributable fraction; CSF = cerebrospinal fluid; ICD = International Classification of Diseases; JEM = job exposure matrix; OPCS = Office of Population Censuses and Surveys; OR = odds ratio; PAF = population attributable fraction; PMR = proportionate mortality ratio; SAR = standardized admission ratio; SIC = Standard Industrial Classification; SMR = standardized mortality ratio; UK = United Kingdom; USA = United States; VGDF = vapors, gas, dust, or fumes.

The median PAF among four population-based studies (top rows) is 10% (range, 3--45%); the median AF within cohorts is 52.5% (range, 38--73%).

PAF for "Occupational PAF of pneumonia" and AF for "Occupational AF of pneumonia in specific cohorts".

We identified nine cohort studies focusing on specific exposures or a single industry ([@bib231]--[@bib239]). Seven estimated risk of pneumonia in welders or in individuals with metal fume exposure ([@bib231], [@bib232], [@bib235]--[@bib239]); two also estimated risk for inorganic dusts ([@bib231], [@bib232]). For metal fume/welding exposures, the median AF was 52.5% (range, 38--73%). Four studies considered risk associated with inorganic dust ([@bib231]--[@bib234]). The AF estimates from these studies varied widely ([Table 11](#tbl11){ref-type="table"}).

Conclusions
===========

This comprehensive literature review and analysis of nonmalignant respiratory disease demonstrates a substantial occupational burden for multiple respiratory conditions not typically considered potentially work related ([Figure 6](#fig6){ref-type="fig"}). The findings for asthma, COPD, and chronic bronchitis build on prior estimates and reinforce the validity of an occupational PAF in the 15--20% range. The occupational contribution to the burden of cases diagnosed as IPF, other interstitial lung diseases, HP and other noninfectious granulomatous diseases (including sarcoidosis), and selected respiratory infections has not been estimated previously using an in-depth literature review and data synthesis approach.

![Summary of the occupational burden of nonmalignant respiratory disease, by condition: the estimated contribution of work exposures to the burden of disease across multiple nonmalignant respiratory conditions. The occupational population attributable fractions for asthma (16%), chronic obstructive pulmonary disease (COPD) (14%), chronic bronchitis (CB) (13%), idiopathic pulmonary fibrosis (IPF) (26%), and community-acquired pneumonia (CAP) (10%) are shown. The occupational burden estimates for pulmonary alveolar proteinosis (PAP) (29%), hypersensitivity pneumonitis (HP) (19%), sarcoid (30%), silica-associated tuberculosis (TB) (2.3%), and healthcare worker--associated TB (HC) (1.0%) are based on mixed methods.](rccm.201904-0717ST_f6){#fig6}

One limitation of this review is that we censored study eligibility for the purposes of data synthesis after December 2017. To address this potential shortcoming, after completing the main analyses, we performed a supplemental literature review covering January through September 2018, identifying three additional publications that would have met criteria for inclusion to estimate occupational burden, one each relevant to COPD, chronic bronchitis, and HP ([@bib240]--[@bib242]). All three studies' results were consistent with our original findings. A 20-year longitudinal follow-up study of 3,343 participants of the population-based European Community Respiratory Survey found that work exposures, assessed by JEM, increased the risk of developing COPD ([@bib240]). The PAF for VGDF yielded by the data from this study was 14.1%, consistent with our estimate. A cross-sectional study of 5,539 Colombians reported increased risk of chronic bronchitis associated with self-reported VGDF exposure, yielding a PAF of 16.1% ([@bib242]), also consistent with our findings. The final recent publication, a U.S. retrospective health claim--based study that estimated the incidence and prevalence of HP, found that 17.0% of HP cases had occupational exposure--associated International Classification of Diseases codes, also consistent with our findings ([@bib241]).

Several other limitations of this in-depth literature review and data synthesis should be noted. The literature we identified was extremely heterogeneous and not amenable to a formal systematic review that could apply all of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) criteria. Thus, we have avoided applying the label "systematic review" to this analysis. In particular, we made no attempt to formally grade publication quality, to apply methodologic restrictions on acceptability (beyond limiting the asthma analysis to prospective studies), or to weight results (beyond taking into account study size in pooled estimates). Study heterogeneity necessitated using differing approaches (e.g., PAF and prevalence) to estimate the occupational contribution to the burden of the various respiratory conditions.

Study heterogeneity also likely contributed to the wide range in the observed values for the estimated occupational burdens within the conditions we studied. To better assess this potential limitation, we also estimated all of the pooled burdens, excluding the highest and lowest values, as well as calculating the median rather than the pooled value. Reanalyses after excluding outlying values yielded point estimates that were similar to the original pooled estimates, as were the median values, neither of which were consistently lower or higher than the initial estimates (data not shown).

Across conditions, a differential in burden estimates is biologically plausible, consistent with differing potencies of risk depending on the nature of the exposure and the pathogenesis of the disease in question. It would be speculative, however, to make causal inferences from these findings, precisely because of the within- and across-condition variability that characterizes this literature.

Yet another limitation of this analysis is that it lacks data that might serve to estimate disability-adjusted life-years lost, a metric that could provide more quantitative assessment of the health impact of different work exposures and comparison across populations. Also of note, this analysis does not include classic pneumoconioses such as silicosis and asbestosis. These are conditions for which the occupational contribution is essentially 100%, obviating the need for an analysis of the estimated burden of those diseases. The pneumoconioses remain important, underrecognized global health problems associated with considerable morbidity and mortality ([@bib243]--[@bib247]).

This assessment of the occupational burden of nonmalignant respiratory disease has clinical, research, and ultimately policy implications. There is a pressing need to improve clinical recognition and widen public health awareness of the contribution of occupational factors across a range of nonmalignant respiratory diseases. Greater attention should be given to reducing this occupational disease burden by identifying and implementing effective preventive interventions. In that light, the importance of preventing these diseases needs to be recognized. Policy makers, especially those who set regulatory standards and oversee their enforcement, should reassess current protections for workers around the world who are exposed to recognized hazardous inhalational exposures.
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